Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019

June 24, 2026 7:05 AM

Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated a Phase 1 clinical trial of VK3019, an investigational dual amylin and calcitonin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found